GRAIL, Inc. $GRAL Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its holdings in shares of GRAIL, Inc. (NASDAQ:GRAL) by 16.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 41,939 shares of the company’s stock after selling 8,100 shares during the period. Pictet Asset Management Holding SA owned approximately 0.09% of GRAIL worth $5,748,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of GRAL. Fifth Third Bancorp increased its stake in shares of GRAIL by 15,733.3% in the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after acquiring an additional 472 shares in the last quarter. Geneos Wealth Management Inc. boosted its stake in GRAIL by 160.0% during the first quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock worth $30,000 after acquiring an additional 360 shares in the last quarter. Allworth Financial LP bought a new position in GRAIL during the second quarter worth $35,000. North Star Investment Management Corp. boosted its stake in GRAIL by 809.1% during the third quarter. North Star Investment Management Corp. now owns 300 shares of the company’s stock worth $42,000 after acquiring an additional 267 shares in the last quarter. Finally, Root Financial Partners LLC acquired a new stake in GRAIL in the third quarter worth $44,000.

Insiders Place Their Bets

In other news, CFO Aaron Freidin sold 23,619 shares of the company’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $146.39, for a total value of $3,457,585.41. Following the completion of the sale, the chief financial officer owned 225,364 shares in the company, valued at $32,991,035.96. This represents a 9.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Andrew Partridge sold 7,873 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $146.39, for a total transaction of $1,152,528.47. Following the completion of the sale, the insider owned 155,865 shares of the company’s stock, valued at approximately $22,817,077.35. The trade was a 4.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 129,944 shares of company stock valued at $14,832,805 in the last three months. 1.83% of the stock is currently owned by insiders.

GRAIL Trading Down 4.5%

Shares of NASDAQ:GRAL traded down $5.46 during mid-day trading on Friday, hitting $115.89. 360,786 shares of the company traded hands, compared to its average volume of 936,290. The stock has a 50-day moving average price of $121.46 and a two-hundred day moving average price of $79.72. GRAIL, Inc. has a 12-month low of $41.50 and a 12-month high of $166.48. The stock has a market cap of $5.21 billion, a P/E ratio of -12.20 and a beta of 2.86.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($2.21) EPS for the quarter, beating analysts’ consensus estimates of ($2.45) by $0.24. GRAIL had a negative return on equity of 16.13% and a negative net margin of 243.80%. The business had revenue of $37.53 million during the quarter, compared to analyst estimates of $44.21 million. As a group, analysts expect that GRAIL, Inc. will post -9.11 earnings per share for the current year.

Analyst Ratings Changes

GRAL has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, October 15th. UBS Group upped their price objective on shares of GRAIL from $105.00 to $175.00 and gave the company a “buy” rating in a report on Friday, October 2nd. Mizuho increased their price objective on shares of GRAIL from $65.00 to $100.00 and gave the stock a “neutral” rating in a research report on Friday, September 25th. Piper Sandler raised their target price on GRAIL from $74.00 to $130.00 and gave the company a “neutral” rating in a research note on Tuesday, November 10th. Finally, Canaccord Genuity Group raised their target price on GRAIL from $80.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 28th. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $128.80.

GRAIL Company Profile

GRAIL, Inc. is a healthcare company developing blood-based tests for the early detection of multiple cancers. Its approach analyzes patterns in cell-free DNA, including DNA methylation signals, to help identify a possible cancer signal and predict its origin in the body. GRAIL’s flagship product is Galleri, a multi-cancer early detection test intended for use alongside—not as a replacement for—recommended cancer screening. The company also conducts clinical research to evaluate the test and advance its early-detection technology.